Selecting the right target and lead indication is one of the most critical choices in a biotech’s trajectory, yet it is rarely straightforward.
For platform organizations, the challenge grows as the search spans millions of potential combinations, far beyond what traditional reviews or internal capacity can manage effectively.
In this white paper, Scitaris co-founder Jonathan Vonnemann, PhD and senior consultant Wignand Mühlhäuser, PhD discuss how structured search and prioritization frameworks help preclinical teams:
Yes. We also assess cognitive ability; successful candidates typically score within the top 5%. Occasionally, we hire for non-consulting roles where experience and relevant expertise may be more important than a PhD.
Yes. We interview key opinion leaders (e.g., healthcare providers and other subject matter experts) to complement analyses as needed.
Yes. We integrate regulatory perspectives into our development strategies and can adapt approaches for FDA, EMA, PMDA, and other regional authorities. This ensures clinical plans are aligned with regulatory expectations worldwide.
Yes. Side entries and inbound lists from investment banks can be integrated at any stage.
